Boker A, Rothenberg L, Hernandez C, Kenyon N S, Ricordi C, Alejandro R
Diabetes Research Institute, Department of Medicine and Surgery, University of Miami School of Medicine, 1450 NW 10th Avenue, Miami, Florida 33136, USA.
World J Surg. 2001 Apr;25(4):481-6. doi: 10.1007/s002680020341. Epub 2001 Apr 11.
New hope for the treatment of type 1 diabetes has recently emerged from the encouraging results of islet cell transplantation in humans during the last few years. Although still facing considerable problems, the challenge to achieving insulin independence has been overcome in some patients who received an islet graft. However, the success of clinical trials is still limited by the inability to transplant enough viable human islets to compensate for the insulin-deficient state, the number of islets that engraft following transplantation, the rejection process, and the recurrence of autoimmunity. The important advances in immunosuppressive regimens, organ procurement techniques, isolation techniques, and availability of defined collagenase blends have contributed to the continuing promise of making islet cell transplantation the treatment of choice for type 1 diabetes mellitus.
近年来，人类胰岛细胞移植取得了令人鼓舞的成果，为1型糖尿病的治疗带来了新希望。尽管仍面临诸多重大问题，但在一些接受胰岛移植的患者中，实现胰岛素自主分泌的挑战已被克服。然而，临床试验的成功仍受到限制，原因包括无法移植足够数量的有活力的人类胰岛以弥补胰岛素缺乏状态、移植后植入的胰岛数量、排斥反应过程以及自身免疫的复发。免疫抑制方案、器官获取技术、分离技术以及特定胶原酶混合物可用性方面的重要进展，为使胰岛细胞移植成为1型糖尿病的首选治疗方法带来了持续的希望。
